Hims & Hers to sell Lilly's Zepbound on its telehealth platform
01/04/2025 18:28
Refiles to correct day in paragraph 1 to Tuesday from Monday April 1 (Reuters) - Telehealth firm Hims & Hers Health HIMS.N said on Tuesday it plans to sell Eli Lilly's LLY.N weight-loss drug Zepbound on its platform. Shares of the company were up 8.5% in afternoon trading. (Reporting by Sneha S K in Bengaluru; Editing by Arun Koyyur) ((Sneha.SK@thomsonreuters.com;))
Recent news on LifeMD
See all newsLifeMD Inc reports results for the quarter ended June 30 - Earnings Summary
LifeMD Q2 revenue misses estimates as shift to branded GLP-1 therapies weighs
Brief: LifeMD Inc Q2 Revenue USD 47.3 Million Vs. IBES Estimate USD 49.2 Million
LifeMD Inc expected to post a loss of 15 cents a share - Earnings Preview
LifeMD Q1 revenue beats estimates on record telehealth subscriber additons